The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids announced the publication of healthcare […]
EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Sonata® […]
2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. – November 11, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the Sonata® 2 System in the United […]
Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and […]
VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal […]
Robust Outcomes Support the Potential of the Sonata System as a First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE […]
Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by […]
Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 – Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its Sonata® System for transcervical treatment of uterine fibroids will be featured in […]
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to […]
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the Sonata® […]
